tiprankstipranks
Trending News
More News >

Matthew B. Klein Insider Profile

4 Followers
Matthew B. Klein, CEO, Director at PTC Therapeutics, holds 387.08K shares in PTC Therapeutics (Ticker: PTCT), holds 50.52K shares in ClearPoint Neuro (Ticker: CLPT). Most recently, Matthew B. Klein Sold ― shares of PTC Therapeutics on Feb 20, 2026 for an estimated value of $511.25K.
tipranks
Matthew B. Klein

Matthew B. Klein
PTC Therapeutics (PTCT)
CEO, Director

Ranked #92,314 out of 106,131 Corporate Insiders

Profitable Transactions

53%
9 out of 17 Profitable Transactions

Average Return

-16.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$25M
98.24%
1.76%
A breakdown of Matthew B. Klein's holdings

Insider Roles

PTC Therapeutics
(PTCT)
CEO, Director
ClearPoint Neuro
(CLPT)
Director
Roles that Matthew B. Klein holds in companies

Most Profitable Insider Trade

Stock:
PTC Therapeutics
(PTCT)
Rating:Informative Sell
Date:Apr 20, 2023 - Apr 20, 2024
Return:+52.90%
The most profitable trade made by Matthew B. Klein

Matthew B. Klein's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
PTC Therapeutics
Feb 20, 2026
CEO, Director
Informative Sell
511.25K
$24.92M
ClearPoint Neuro
May 19, 2025
Director
Uninformative Buy
278.01K
$446.33K
List of latest transactions for each holding click on a transaction to see Matthew B. Klein's performance on stock

Matthew B. Klein insider profile FAQ

What is the percentage of profitable transactions made by Matthew B. Klein?
The percentage of profitable transactions made by Matthew B. Klein is 53%.
    What is the average return per transaction made by Matthew B. Klein?
    The average return per transaction made by Matthew B. Klein is -16.50%.
      What stocks does Matthew B. Klein hold?
      Matthew B. Klein holds: PTCT, CLPT stocks.
        What was Matthew B. Klein’s latest transaction?
        Matthew B. Klein latest transaction was an Informative Sell of $511.25K.
          What was Matthew B. Klein's most profitable transaction?
          Matthew B. Klein’s most profitable transaction was an Informative Sell of PTCT stock on April 20, 2023. The return on the trade was 52.90%.
            What is Matthew B. Klein's role in PTC Therapeutics?
            Matthew B. Klein's role in PTC Therapeutics is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.